Argentina vs Bosnia and Herzegovina: Percentage of bloodstream infection due to Escherichia coli resistant
Argentina
22.5%
in 2022
Bosnia and Herzegovina
26.8%
in 2022
Argentina rank
31st
Bosnia and Herzegovina rank
28th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Argentina
- Bosnia and Herzegovina
How they compare
Bosnia and Herzegovina currently reports 26.8% against 22.5% in Argentina, a difference of 4.3%.
That makes Bosnia and Herzegovina's figure about 1.2 times Argentina's.
Across all 6 years both countries report, Bosnia and Herzegovina has been ahead every year.
Argentina ranks 31st and Bosnia and Herzegovina ranks 28th of 50 countries.
Bosnia and Herzegovina has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Argentina | Bosnia and Herzegovina | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 19.1% | 21.8% | 2.7% | Bosnia and Herzegovina |
| 2020s | 21.1% | 26.4% | 5.2% | Bosnia and Herzegovina |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Argentina or Bosnia and Herzegovina?
- Bosnia and Herzegovina, at 26.8% against 22.5% in Argentina as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Argentina and Bosnia and Herzegovina?
- 4.3%, with Bosnia and Herzegovina ahead.
- How many years of comparable data are there for Argentina and Bosnia and Herzegovina?
- 6 years are reported by both, from 2017 to 2022.
- How do Argentina and Bosnia and Herzegovina rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Argentina ranks 31st and Bosnia and Herzegovina ranks 28th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.